International Journal of Cancer最新文献

{"title":"Beneficial effects of aerobic exercises on multiple myeloma: Mechanisms and clinical observations.","authors":"Siyao He, Jingjing Wen, Zhongqing Zou, Linfeng Li, Xiaohui Zhao, Xiang Liu, Hongmei Luo, Jingcao Huang, Ziyue Mi, Yue Zhang, Qianwen Gao, Haonan Yang, Yu Feng, Xinyu Zhai, Fangfang Wang, Ting Niu, Li Zhang, Yuhuan Zheng","doi":"10.1002/ijc.70032","DOIUrl":"https://doi.org/10.1002/ijc.70032","url":null,"abstract":"<p><p>Studies on multiple myeloma (MM), the second most common hematologic malignancy, have shown inconclusive results regarding the role of exercise in treatment. This study evaluated the relationship between physical exercise and MM treatment outcomes. In the 5T-MM mouse model, tumor-bearing mice underwent treatment that included bortezomib and dexamethasone alongside 6 weeks of low- or moderate-intensity treadmill aerobic training. Tumor burden and survival data were recorded. Additionally, a retrospective analysis was conducted on 65 MM patients undergoing maintenance therapy at West China Hospital from 2013 to 2024. Patients were categorized based on their adherence to the World Health Organization (WHO) physical activity guidelines, and progression-free survival and progression-free survival in maintenance therapy were analyzed. In the mouse model, the combination of dual-drug therapy and exercise improved outcomes, extending survival by more than 10 days. Aerobic exercises reduced regulatory T cells and increased NK cells in the peripheral blood of mice. In the exercise group of mice, myokines IL-15 and irisin were up-regulated, implying both myokines could contribute to the regulation of anti-MM immunity. In the patient study, patients who met the WHO physical activity recommendations demonstrated significantly better progression-free survival (PFS) and progression-free survival in maintenance treatment (PFSm). Overall, appropriate aerobic exercises may benefit some MM patients, suggesting a potential for exercise as an adjunct in MM treatment.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of a real-world cohort identifies geranylgeranyl diphosphate synthase 1 as a predictor of chemoresistance in small cell lung cancer.","authors":"Yi Deng, Chenchen Guo, Tengfei Zhang, Yuan Chen, Xin Zhang, Hongbin Ji, Liang Hu","doi":"10.1002/ijc.70036","DOIUrl":"https://doi.org/10.1002/ijc.70036","url":null,"abstract":"<p><p>A subset of patients with small cell lung cancer (SCLC) exhibit intrinsic resistance to chemotherapy. However, biomarkers that effectively predict this group of patients are still lacking. We previously reported that high geranylgeranyl diphosphate synthase 1 (GGPS1) expression is associated with poor overall survival (OS) in SCLC, and statin combination therapy is effective in overcoming chemoresistance, especially in GGPP-high SCLC. However, the expression patterns of GGPS1 in SCLC subtypes and its relationship with clinical chemotherapy response remain unclear, and whether GGPS1 indicates statin treatment sensitivity in chemoresistant SCLC needs further validation. Through integrative analyses of 146 real-world SCLC cases, we found that approximately 25% exhibited high GGPS1 expression. Subgroup analysis revealed that GGPS1 expression was higher in the ASCL1/NEUROD1/POU2F3 triple-negative subgroup. Moreover, high GGPS1 expression was significantly correlated with reduced objective response rate (ORR) and progression-free survival (PFS) as well as OS. In addition, analysis of seven paired biopsy samples demonstrated that GGPS1 was upregulated in chemoresistant SCLC. We further showed that the combination of etoposide and cisplatin (E/P) with statins had improved efficacy in a patient-derived xenograft (PDX) model derived from a relapsed patient with high GGPS1 expression. Our findings suggest that GGPS1 is a promising biomarker for predicting chemoresistance in SCLC and may be a potential indicator of sensitivity to statin combination therapy in chemoresistant SCLC.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Washed microbiota transplantation alleviates tyrosine kinase inhibitors associated gastrointestinal adverse effects.","authors":"Weihong Wang, Xinyi He, Chenchen Liang, Yaxue Wang, You Yu, Faming Zhang","doi":"10.1002/ijc.70034","DOIUrl":"https://doi.org/10.1002/ijc.70034","url":null,"abstract":"<p><p>Gut microbiota dysbiosis is implicated in tyrosine kinase inhibitor (TKI)-induced gastrointestinal adverse effects (GAEs), often necessitating medication adjustments or discontinuation in severe or persistent cases. This study aimed to evaluate the efficacy and safety of washed microbiota transplantation (WMT) in managing TKI-induced GAEs. This prospective study involved cancer patients presenting TKI-induced GAEs. The primary outcome was the clinical remission rate at Week 8 post-WMT, which was assessed by the common terminology criteria for adverse events grade. The secondary outcomes included the clinical asymptomatic rate, the onset time of clinical remission, and the variation of C-reactive protein (CRP) levels. Twenty-four patients undergoing 66 WMTs were analyzed. The overall clinical remission and asymptomatic rates were 75.00% (18/24) and 29.17% (7/24), respectively. GAEs, including diarrhea, abdominal pain, and abdominal distention, showed significant improvement post-WMT (all p < .05), while hematochezia exhibited a decreasing trend in severity. Median time to remission was 14.5 days (inter-quartile range, 7-24). Within 8 weeks post-WMT, three initially responsive patients experienced relapse. CRP levels significantly decreased (p < .05), and no severe adverse events were reported. This study proposes WMT as a potential treatment for TKI-induced GAEs, particularly for patients who do not respond adequately to conventional treatments.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mode of delivery and the risk of lymphoblastic leukemia during childhood-A Swedish population-based cohort study.","authors":"Christina-Evmorfia Kampitsi, Hanna Mogensen, Mats Heyman, Maria Feychting, Giorgio Tettamanti","doi":"10.1002/ijc.70027","DOIUrl":"https://doi.org/10.1002/ijc.70027","url":null,"abstract":"<p><p>Cesarean section (CS) rates have been increasing beyond medically warranted thresholds, despite potential long-term adverse outcomes. Previous research on CS delivery and childhood leukemia is conflicting but suggests an increased acute lymphoblastic leukemia (ALL) risk in children delivered by planned CS. It has been suggested that maternal and pregnancy conditions predisposing to pregnancy complications might confound such an association; therefore, we aimed to elucidate the relationship between delivery mode and ALL in Swedish children. To this end, we studied all children born in Sweden between 1982-1989 and 1999-2014, when comprehensive information on delivery mode was available (n = 2,442,330). Pregnancy conditions, delivery mode, and childhood ALL diagnoses (<20 years) were retrieved from nationwide registers. Cox proportional hazards regression was used to assess the association between delivery mode and childhood ALL, adjusting for maternal and pregnancy conditions. We observed an increased ALL risk among children delivered by planned CS (HR = 1.21, 95% CI 0.96-1.54), driven by B-cell precursor ALL (HR = 1.29, 95% CI 1.01-1.67). The associations were concentrated among boys and at peak ages of ALL incidence (≤5 years) and persisted after accounting for potential confounders, including maternal and perinatal factors. Unplanned CS was not associated with increased risk of childhood ALL. Our nationwide study supports an association between planned CS and an increased B-cell precursor ALL risk in Swedish children, irrespective of maternal and pregnancy conditions. Possible underlying mechanisms, such as lack of exposure to maternal vaginal microbiota or decreased stress hormones at birth, require further exploration.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline vitamin D status, genetic susceptibility, and the risk of incident hepatocellular carcinoma.","authors":"Chengxiao Yu, Fei Lin, Chan Tian, Haiyan Guo, Jing Lu, Wen Guo, Qingning Duan, Longfeng Jiang, Qun Zhang, Ci Song","doi":"10.1002/ijc.70003","DOIUrl":"https://doi.org/10.1002/ijc.70003","url":null,"abstract":"<p><p>High vitamin D concentrations may reduce the incidence of hepatocellular carcinoma (HCC), though results have been inconsistent. This study aimed to evaluate the association between serum 25-hydroxyvitamin D (25(OH)D) levels and HCC, and to assess whether the genetic risk of HCC modifies this association. The prospective cohort study involved 447,028 individuals free of liver diseases in the UK Biobank. Serum 25(OH)D concentrations were measured by the chemiluminescent immunoassay method. The associations were evaluated using the Cox proportional hazards model, estimating hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Additionally, the weighted polygenic risk score (PRS) of HCC was calculated by 5 SNPs reported in a previously published genome-wide association study (GWAS). During a median follow-up of 12.5 years, 377 cases of HCC were documented. Compared to the lowest quartile of serum 25(OH)D, the HR (95% CI) of HCC was 0.52 (0.38-0.70) in the highest quartile. Per 10 nmol/L increase in serum 25(OH)D was associated with a 12% lower HCC risk (95% CI: 7%-17%). A joint effect of genetic and serum 25(OH)D on HCC risk was observed. Those with low genetic risk of HCC and the highest serum 25(OH)D had a HR (95% CI) of 0.22 (0.11-0.45) compared to those with high genetic risk of HCC and the lowest 25(OH)D serum levels, but there was no interaction (p interaction = 0.529). Our findings emphasize that higher serum 25(OH)D levels are linked to a reduced risk of HCC, indicating the potential role of 25(OH)D in the primary prevention of HCC.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.","authors":"Yong Liu, Qiang Xue, Baogui Wang, Xuewei Ding, Rupeng Zhang, Xiaona Wang, Bin Ke, Xuejun Wang, Ning Liu, Jingyu Deng, Hongjie Zhan, Bin Li, Liangliang Wu, Mingzhi Cai, Li Zhang, Wenbai Huang, Peng Jin, Han Liang","doi":"10.1002/ijc.35511","DOIUrl":"https://doi.org/10.1002/ijc.35511","url":null,"abstract":"<p><p>In selected patients with stage IV gastric cancer, radical surgery after conversion therapy may increase survival benefit; however, there is currently no standard protocol for conversion therapy. We explored the feasibility and efficacy of sintilimab plus two-drug chemotherapy (S-1 plus nab-paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China. This was a prospective, single-arm, single-center, phase 2 study. The primary endpoint was the R0 conversion rate, defined as the proportion of R0 surgical patients to the total number of patients treated. Of 56 patients screened, 47 were enrolled, received preoperative treatment, and were evaluated for tumor response. Most patients (28/47; 59.6%) had two or three unresectable factors. The objective response rate and disease control rate were 53.2% and 97.9%, respectively. Of the 46/47 patients who achieved disease control, 35 underwent surgery. The R0 conversion rate was 51.1% (24/47). A pathological complete response was observed in 14.3% (5/35) of patients. Median overall survival and event-free survival were 25.7 and 15.3 months, respectively. Overall survival and event-free survival were significantly better in surgical patients compared with non-surgical patients (p < 0.001). In the surgical population, R1/R2 resection was the only significant independent predictor of unfavorable event-free survival by multivariate analysis (p = 0.015). There were no chemotherapy- or perioperative-related deaths. The safety profile was manageable. Sintilimab plus chemotherapy and apatinib followed by conversional resection may be a new feasible and safe option for initially unresectable gastric cancer, potentially leading to long-term survival or even cure.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and risks of recurrence and progression among patients with non-muscle invasive bladder cancer.","authors":"Ivy Beeren, Joann Kiebach, Jasper P Hof, Laurien M Buffart, Katja K H Aben, J Alfred Witjes, Antoine G van der Heijden, Lambertus A L M Kiemeney, Alina Vrieling","doi":"10.1002/ijc.70030","DOIUrl":"https://doi.org/10.1002/ijc.70030","url":null,"abstract":"<p><p>Previous studies in solid tumors link high physical activity (PA) levels to lower cancer recurrence risk, but evidence is lacking for patients with non-muscle invasive bladder cancer (NMIBC). We evaluated the association between (changes in) PA (total, moderate-to-vigorous PA, leisure-time PA, and Dutch PA guideline adherence) and risks of NMIBC recurrence and progression. Patients diagnosed between 2014 and 2021 were recruited for the multi-center prospective cohort UroLife. Participants reported prediagnosis PA at 6 weeks (n = 1414) and postdiagnosis PA at 3 and 15 months after diagnosis (n = 1275). Multivariable proportional hazards models were used to assess the association of PA levels with risk of first and multiple recurrence(s) and progression. During a median total follow-up time of 4.6 years, 501 patients had ≥1 recurrence, 144 had ≥2 recurrences, and 157 had progression. Higher pre- and postdiagnosis PA levels were not significantly associated with risks of first recurrence, multiple recurrences, and progression. Pre-to-postdiagnosis increases of 10 metabolic equivalent of task hour/week in leisure-time PA, equivalent to 3-4 h/week of walking or 1 h/week of running, were significantly associated with lower progression risk (hazard ratio at 3 months: 0.94, 95% confidence interval: 0.89-0.99). The self-reported and relatively high PA levels could have limited the detection of associations. In conclusion, higher PA levels before or after NMIBC diagnosis were not significantly associated with lower recurrence or progression risk. Although pre-to-postdiagnosis increases in leisure-time PA were associated with lower progression risk, further research is necessary before specific PA recommendations can be formulated for patients with NMIBC.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144525717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of and differences in participation restrictions among US cancer survivors.","authors":"Todd Burus, Nicholas Lamar Wright, Jennifer D Burus, Laurie E McLouth, Krystle A Lang Kuhs","doi":"10.1002/ijc.70029","DOIUrl":"https://doi.org/10.1002/ijc.70029","url":null,"abstract":"<p><p>Being diagnosed with cancer and undergoing cancer treatment can have detrimental effects on the physical and mental functioning of individuals. Understanding the prevalence and specific differences in functioning difficulties experienced by cancer survivors can enhance future research. In this cross-sectional study of self-reported functioning, we used a United States (US) nationally representative sample of adults aged ≥20 years (n = 7764) to assess for differences in the prevalence of participation restrictions based on the global standard Washington Group on Disability Statistics Short Set on Functioning. We measured differences using adjusted prevalence ratios (aPR) with 95% confidence intervals (CI), adjusted for sex, age, race and ethnicity, and educational attainment. Significant aPR differences were determined based on 95% CIs not including 1. Our final analytic sample included 908 cancer survivors (weighted prevalence, 9.1%; 95% CI, 8.4%-9.8%). We estimated that participation restrictions were 43.3% more common among cancer survivors than individuals with no cancer history (aPR, 1.433; 95% CI, 1.202-1.709). Among specific domains of functioning, cancer survivors experienced a significantly greater prevalence of difficulties with seeing, hearing, mobility, communicating, cognition, self-care, and upper-body functioning. Given the increasing number of cancer survivors in the US, it is crucial to develop interventions to reduce participation restrictions among this population and provide equal opportunities to fully engage in life without additional barriers.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144525718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of SPP1⁺TAMs in cancer: Impact on patient prognosis and future therapeutic targets.","authors":"Xiang Li, Jie Lian, Haibo Lu","doi":"10.1002/ijc.70018","DOIUrl":"https://doi.org/10.1002/ijc.70018","url":null,"abstract":"<p><p>Tumor-associated macrophages (TAMs) are a critical population of immune cells that infiltrate the tumor microenvironment (TME) and significantly influence cancer progression, prognosis, and treatment. SPP1⁺TAMs represent a tumor-promoting subset of TAMs characterized by their ability to secrete osteopontin, along with various cytokines and chemokines, and to interact with a diverse array of ligands. Within the tumor microenvironment, SPP1⁺TAMs are primarily localized to hypoxic and necrotic regions, as well as along the tumor margins. Studies have shown that SPP1⁺TAMs promote tumor angiogenesis, invasion, metastasis, and immunosuppression. The infiltration of SPP1⁺TAMs has been associated with poor prognosis in cancer patients. Furthermore, their presence may influence disease progression and treatment response. Targeting SPP1⁺TAMs has the potential to reduce immunosuppression and augment immunotherapeutic efficacy, thereby contributing to improved treatment outcomes.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy as an organ-preserving alternative to surgery in patients with locally advanced esophageal squamous cell carcinoma achieving major pathologic response after induction immunochemotherapy.","authors":"Xin-Yun Song, Lin Lin, Yang Yang, Hui-Hui Hu, Hong-Xuan Li, Wen Feng, Qin Zhang, Xu-Wei Cai, Xiao-Long Fu, Zhi-Gang Li, Jun Liu, Wen Yu","doi":"10.1002/ijc.35515","DOIUrl":"https://doi.org/10.1002/ijc.35515","url":null,"abstract":"<p><p>With the advancement of immunotherapy, neoadjuvant immunochemotherapy has emerged as an effective approach for treating locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, whether radiotherapy can serve as a reliable organ-preserving alternative following induction immunochemotherapy (IICT), and which patient subgroups benefit most, remains uncertain. In this retrospective study, 388 patients with LA-ESCC were analyzed, including 299 who underwent surgery and 89 who received radiotherapy after IICT. Responses to immunochemotherapy were classified as major pathologic response (MPR) or non-MPR based on pathologic examination for surgical patients and a previously developed MPR predictive model for radiotherapy patients. Survival outcomes were assessed using the Kaplan-Meier method, while prognostic factors were evaluated through Cox regression analyses. Propensity score matching (PSM) was used to minimize confounding factors. Surgery was associated with better progression-free survival (PFS) compared to radiotherapy (p = 0.002 before PSM; p = 0.017 after PSM), but no significant difference in overall survival (OS) was observed (p = 0.144 before PSM; p = 0.241 after PSM). Among MPR patients, radiotherapy achieved PFS and OS outcomes similar to surgery (PFS: p = 0.136; OS: p = 0.255) after PSM. Failure patterns differed, with local or regional recurrence being more common in the radiotherapy group, while distant metastasis was prevalent in surgery patients. Major postoperative complications occurred in 9.36% of surgery patients, and 11.2% of radiotherapy patients had grade 3-4 adverse events. These findings indicate that radiotherapy could be a safe and effective organ-preserving alternative for LA-ESCC patients, especially those achieving MPR, offering more personalized and less invasive treatment options while maintaining quality of life.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}